Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDER Attacks Genentech's Plans For New Confirmatory Trial At Avastin Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

Proposed study of bevacizumab in first-line metastatic breast cancer is unlikely to substantiate the magnitude of progression-free survival benefit seen in the E2100 trial, Division of Biologic Oncology Products Director Patricia Keegan says.

You may also be interested in...



Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns

Genentech’s proposal to run a new confirmatory trial of Avastin (bevacizumab) while the first-line metastatic breast cancer claim remains on label was undermined by practical considerations raised at the June 28-29 hearing on CDER's proposal to withdraw the indication.

Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns

Genentech’s proposal to run a new confirmatory trial of Avastin (bevacizumab) while the first-line metastatic breast cancer claim remains on label was undermined by practical considerations raised at the June 28-29 hearing on CDER's proposal to withdraw the indication.

Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?

FDA Commissioner Margaret Hamburg faces a decision on the future of Avastin’s (bevacizumab) first-line metastatic breast cancer claim that may not be so cut and dried as the Oncologic Drugs Advisory Committee’s unanimous vote favoring the indication’s withdrawal suggests.

Related Content

Topics

UsernamePublicRestriction

Register

PS072434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel